Menu
Recruiting NCT06915974

Comparison Between Interleukin 6 and Procalcitonin in Detecting Sepsis and Incidence of Mortality in Burn ICU Patients

No phase Interventional Burns Sepsis Septic Shock Death

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Interleukin 6.
Who it may be relevant to
Registry conditions: Burns, Sepsis, Septic Shock, Death. Basic parameters: 25 years — 60 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Egypt
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

The investigators will compare the efficacy of Interleukin-6 (IL-6) as a better indicator than procalcitonin in burn patients with sepsis or septic shock regarding success of treatment and early ICU discharge.

Detailed description

Interleukin 6 and procalcitonin will be sampled for all patients on days 1, 3, 7, and 10.

Treatment plan will be initiated to all patients according to the burn ICU protocol.

According to the lab results, interleukin 6 and procalcitonin will guide the investigators to take decisions regarding clinical improvement and ICU stay.

Interventions

  • Diagnostic test Interleukin 6
    Interleukin 6 and procalcitonin will be sampled for all patients on days 1, 3, 7, and 10

Primary outcome measures

  • Occurrence of sepsis and septic shock [Time frame: From day 1 to day 10 in burn ICU]
Secondary outcome measures (1)
  • Length of ICU stay [Time frame: One month after ICU admission]

Eligibility criteria

Inclusion criteria

  • Patients with acute burn admitted to burn ICU within 24 hours from the burn incidence.
  • patients with burn percentage of 25% to 50% of total body surface area
  • patients with second to third degree burns
  • ASA 1 and ASA 2 patients

Exclusion criteria

  • Burn percentage more than 50% or less than 25% of total body surface area
  • Having autoimmune diseases
  • Cancer patients
  • ASA 3 and ASA 4 patients

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Other

Study locations

Egypt · 1 center
  • Ain Shams University — Cairo

Identifiers

NCT: NCT06915974 · FMASU MS 10/2024/2025

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗